These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25819895)

  • 1. Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population.
    Genovesi S; Porcu L; Luise MC; Riva H; Nava E; Stella A; Pozzi C; Ondei P; Minoretti C; Gallieni M; Pontoriero G; Conte F; Torri V; Vincenti A
    Int J Cardiol; 2015; 186():170-7. PubMed ID: 25819895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal dialysis as a risk factor for appropriate therapies and mortality in implantable cardioverter-defibrillator recipients.
    Robin J; Weinberg K; Tiongson J; Carnethon M; Reddy M; Ciaccio C; Quadrini M; Hsu J; Fan J; Choi P; Kadish A; Goldberger J; Passman R
    Heart Rhythm; 2006 Oct; 3(10):1196-201. PubMed ID: 17018351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
    Jukema JW; Timal RJ; Rotmans JI; Hensen LCR; Buiten MS; de Bie MK; Putter H; Zwinderman AH; van Erven L; Krol-van Straaten MJ; Hommes N; Gabreëls B; van Dorp W; van Dam B; Herzog CA; Schalij MJ; Rabelink TJ;
    Circulation; 2019 Jun; 139(23):2628-2638. PubMed ID: 30882234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.
    Pun PH; Hellkamp AS; Sanders GD; Middleton JP; Hammill SC; Al-Khalidi HR; Curtis LH; Fonarow GC; Al-Khatib SM
    Nephrol Dial Transplant; 2015 May; 30(5):829-35. PubMed ID: 25404241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States.
    Charytan DM; Patrick AR; Liu J; Setoguchi S; Herzog CA; Brookhart MA; Winkelmayer WC
    Am J Kidney Dis; 2011 Sep; 58(3):409-17. PubMed ID: 21664735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death.
    Cuculich PS; Sánchez JM; Kerzner R; Greenberg SL; Sengupta J; Chen J; Faddis MN; Gleva MJ; Smith TW; Lindsay BD
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):207-13. PubMed ID: 17338717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Important differences in mode of death between men and women with heart failure who would qualify for a primary prevention implantable cardioverter-defibrillator.
    Rho RW; Patton KK; Poole JE; Cleland JG; Shadman R; Anand I; Maggioni AP; Carson PE; Swedberg K; Levy WC
    Circulation; 2012 Nov; 126(20):2402-7. PubMed ID: 23072904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators.
    Herzog CA; Li S; Weinhandl ED; Strief JW; Collins AJ; Gilbertson DT
    Kidney Int; 2005 Aug; 68(2):818-25. PubMed ID: 16014061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of end-stage renal failure and hemodialysis on mortality rates in implantable cardioverter-defibrillator recipients.
    Hreybe H; Razak E; Saba S
    Pacing Clin Electrophysiol; 2007 Sep; 30(9):1091-5. PubMed ID: 17725751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do implantable cardioverter defibrillators improve survival in patients with chronic kidney disease at high risk of sudden cardiac death? A meta-analysis of observational studies.
    Makki N; Swaminathan PD; Hanmer J; Olshansky B
    Europace; 2014 Jan; 16(1):55-62. PubMed ID: 24058182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis.
    Koman E; Gupta A; Subzposh F; Saltzman H; Kutalek SP
    J Interv Card Electrophysiol; 2016 Mar; 45(2):219-23. PubMed ID: 26768264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive effectiveness of implantable cardioverter defibrillator in reducing sudden cardiac death in the Chinese population: a multicenter trial of ICD therapy versus non-ICD therapy.
    Hua W; Niu H; Fan X; Ding L; Xu YZ; Wang J; Chen K; Wang F; Zhang S;
    J Cardiovasc Electrophysiol; 2012 Nov; 23 Suppl 1():S5-9. PubMed ID: 23140347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
    Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
    Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of current implantable cardioverter defibrillator guidelines application for primary prevention of sudden cardiac death in Latin American patients with heart failure: a cross-sectional study.
    Gonzalez-Zuelgaray J; Pellizon O; Muratore CA; Oropeza ES; Rabinovich R; Ramos JL; Tentori MC; Reyes N; Aguayo R; Marin J; Peterson BJ
    Europace; 2013 Feb; 15(2):236-42. PubMed ID: 22968848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sudden cardiac death in dialysis: do current guidelines for implantable cardioverter defibrillator therapy apply to patients with end-stage kidney disease?
    O'Shaughnessy MM; Lappin DW; Reddan DN
    Semin Dial; 2012 May; 25(3):272-6. PubMed ID: 22452711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
    Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
    Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience.
    Conte G; Sieira J; Ciconte G; de Asmundis C; Chierchia GB; Baltogiannis G; Di Giovanni G; La Meir M; Wellens F; Czapla J; Wauters K; Levinstein M; Saitoh Y; Irfan G; Julià J; Pappaert G; Brugada P
    J Am Coll Cardiol; 2015 Mar; 65(9):879-88. PubMed ID: 25744005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of Implantable Cardioverter Defibrillator Therapy and Mortality in Primary and Secondary Prevention of Sudden Cardiac Death.
    Konstantino Y; Shafat T; Novack V; Novack L; Amit G
    Isr Med Assoc J; 2015 Dec; 17(12):760-3. PubMed ID: 26897978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic implantable cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation.
    Fröhlich GM; Holzmeister J; Hübler M; Hübler S; Wolfrum M; Enseleit F; Seifert B; Hürlimann D; Lehmkuhl HB; Noll G; Steffel J; Falk V; Lüscher TF; Hetzer R; Ruschitzka F
    Heart; 2013 Aug; 99(16):1158-65. PubMed ID: 23813845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.